BCL2 and cancer: Consequently, mutations that lead to the overexpression of Bcl-2 or to the impairment of the p53 pathway play pivotal roles not only in the development and progression of cancer, but also in the resistance to chemo- and radiotherapy that develops in established tumors [2], [7].